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Introduction
Polycyclic aromatic hydrocarbons such as benzo [a] pyrene (BaP) are environmental pollutants produced by the combustion of cigarettes, creosote railroad ties, and coke ovens (Miller and Ramos, 2001; Uno and Makishima, 2009) . BaP is implicated as a causative agent in malignancies, such as lung and head-and-neck cancers, and atherosclerosis as a consequence of cigarette smoking (Alexandrov et al., 2010; Shimada and Fujii-Kuriyama, 2004) . BaP inhalation activates the aryl hydrocarbon receptor (AHR), which forms an active transcription factor heterodimer with the AHR nuclear translocator, and induces expression of a group of genes called the [Ah] gene battery, which includes the phase I enzymes [cytochrome P450 (CYP) 1A1 (gene symbol, CYP1A1), CYP1A2, CYP1B1, and NAD(P)H:quinone oxidoreductase 1] and the phase II enzymes (glutathione S-transferase A1 and UDP glucuronosyltransferase 1A6) (Nebert et al., 2000) .
BaP mediates carcinogenic, mutagenic and cytotoxic effects after conversion to toxic metabolites through an AHR-dependent mechanism of metabolic activation (Miller and Ramos, 2001; Shimada and Fujii-Kuriyama, 2004) . BaP is first oxidized by CYP1A1 and CYP1B1 to phenols, such as 3-hydroxy-BaP and 9-hydroxy-BaP, and epoxides, such as BaP-7,8-epoxide (Shimada, 2006; Uno and Makishima, 2009) . BaP-7,8-diol-9,10-epoxide. Among the metabolites in BaP-treated cells, (+)-BaP-7,8-diol-9,10-epoxide-2 is the most reactive carcinogen (Alexandrov et al., 2010; Shimada, 2006) .
Original studies on mutant Hepa-1 cells that are resistant to BaP-induced growth suppression have shown that BaP resistance is associated with mutations in the Cyp1a1 gene and dysfunction of the AHR transcription factor (Hankinson et al., 1991) .
Expression of exogenous CYP1A1 in CYP1A1-deficient cells restores the formation of
BaP-induced DNA adducts (Maier et al., 2002) . These findings indicate that metabolic activation of BaP requires the AHR-CYP1A1 cascade. In contrast, BaP-induced DNA adducts are increased in the liver and BaP clearance from the blood is slower in CYP1A1-null mice (Uno et al., 2001 ). Overexpression of CYP1A1 in hepatocytes suppresses BaP-induced DNA adduct formation and AHR transactivation (Endo et al., 2008) . CYP1A1 may be involved in both metabolic activation and detoxification of BaP depending on conditions (Uno et al., 2006 (Choi and Makishima, 2009; Nagpal et al., 2005) . Natural and synthetic VDR ligands inhibit the proliferation and/or induce the differentiation of various types of malignant cells, including myeloid leukemia This article has not been copyedited and formatted. The final version may differ from this version. (Hozumi, 1998; Nagpal et al., 2005) . On ligand binding, VDR undergoes conformational changes that result in dynamic interaction with the heterodimer partner retinoid X receptor (RXR; NR2B) and exchange of cofactor complexes (Makishima and Yamada, 2005) . Corepressors bind to the VDR-RXR heterodimer in the absence of ligand and ligand binding reduces the affinity of corepressors and increases the affinity for coactivators, a structural transition that induces transcription of specific genes. The VDR-RXR heterodimer binds preferentially to a vitamin D response element that consists of a two hexanucleotide (AGGTCA or a related sequence) direct repeat motif separated by three nucleotides. An inverted palindrome of the hexanucleotide motif, also called everted repeat (ER) element (Mangelsdorf and Evans, 1995) , separated by six, seven, eight, or nine nucleotides has been also identified as vitamin D response elements in genes including CYP3A4 (Choi and Makishima, 2009; Thummel et al., 2001) . VDR has been found to act as a receptor for secondary bile acids, including lithocholic acid (LCA) and 3-ketocholanic acid, and to induce the expression of CYP3A enzymes (Makishima et al., 2002) . CYP3A enzymes catalyze the metabolic conversion of a wide variety of xenobiotics and endogenous substrates, including bile acids, to more polar derivatives (Xie and Evans, 2001) .
VDR belongs to the NR1I nuclear receptor subfamily along with pregnane X receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3), both of which play a role in the regulation of xenobiotic metabolism. These findings suggest that This article has not been copyedited and formatted. The final version may differ from this version. (Yoshinari et al., 2010) . In this study, we report that VDR activation enhances AHR-induced CYP1A1 expression in human macrophage-derived cells.
This article has not been copyedited and formatted. The final version may differ from this version. [ (25S)-26-adamantyl-1α,25-dihydroxy-2-methylene-22,23-didehydro-19,27-dinor-20-ep i-vitamin D 3 ] were synthesized in the Sachiko Yamada laboratory (Igarashi et al., 2007; Ishizawa et al., 2008; Nakabayashi et al., 2008 Total RNAs from samples were prepared by the acid guanidine thiocyanate-phenol/chloroform method Tavangar et al., 1990 ).
This article has not been copyedited and formatted. The final version may differ from this version. Other primers were reported previously ). The RNA values were normalized to the amount of β-actin mRNA, or mRNA copy numbers were determined using expression plasmids for a standard curve in real-time PCR reactions (Uno et al., 2006) .
Western Blotting Analysis. For VDR and AHR expression, nuclear extracts were prepared as previously described (Inaba et al., 2007; Schreiber et al., 1989) . For CYP1A1 expression, microsomes (S9 fraction) from cells were prepared as previously described (Endo et al., 2008; Uno et al., 2001 anti-β-actin antibody (Sigma-Aldrich), visualized with an enhanced chemiluminescence detection system or an alkaline phosphatase conjugate substrate system (Endo et al., 2008) .
Enzyme Activity Assays. Extracts from microsomal fractions were subjected for enzyme activity assays. BaP hydroxylation was assayed as previously reported (Endo et al., 2008; Nebert and Gelboin, 1968) . Briefly, 200 μ g of microsomal protein was incubated in 100 mM potassium phosphate buffer (pH 7.4) containing 1 mg/ml bovine serum albumin, 80 μM BaP and 0.5 mM NADPH at 37°C for 20 minutes. The reaction was stopped by the addition of acetone/n-hexane (1:3). After the organic phase was extracted with NaOH, the concentration of 3-hydroxy-BaP was measured spectrofluorometrically with activation at 396 nm and fluorescence at 522 nm.
Measurement of DNA Adducts. BaP-induced DNA adducts were determined by a 32 P-postlabeling method (Endo et al., 2008; Talaska et al., 1996; Uno et al., 2001) . After DNA extraction from cells, hydrolysis to 3'-phosphodeoxynucleotides with micrococcal endonuclease and spleen phosphodiesterase, and removal of non-adducted 3'-phosphodeoxynuleotides with n-butanol extraction, the 3'-phosphodeoxynucleosides were labeled at the 5' positions with [ 32 P]ATP and T4 polynucleotide kinase.
Two-dimensional thin-layer chromatography on polyethylenimine cellulose sheets was used to resolve the 32 P-labeled DNA adducts (Randerath and Randerath, 1964) 8.5% glycerol, 1 mM dithiothreitol, 0.5 μg/ml poly(dI-dC), 0.1% Triton-X100, and nonfat milk. Unlabeled probes and anti-VDR antibody (Santa Cruz Biotechnology) were used for competition experiments and supershift experiments, respectively. Samples were separated on 5% polyacrylamide gels and were visualized with autoradiography.
Chromatin Immunoprecipitation. Chromatin immunoprecipitation (ChIP) was performed as reported previously Shang et al., 2000) . After nuclear proteins were cross-linked to DNA in 1% formaldehyde for 15 min, cells were This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1A) . Interestingly, CYP1A1 mRNA expression induced by BaP was further increased by co-administration of 1,25(OH) 2 D 3 in these cells (Fig. 1A ).
Combined BaP and 1,25(OH) 2 D 3 treatment also increased CYP1A1 mRNA expression to a higher degree than by BaP alone in breast cancer MCF-7 cells and in kidney epithelium-derived HEK293 cells (Fig. 1A) . Previous reports have demonstrated expression of functional VDR and AHR proteins in U937 cells, THP-1 cells, MCF-7 cells and HEK293 cells Campbell et al., 2000; Hayashi et al., 1995; Inaba et al., 2007; Ishizawa et al., 2008; Zhang et al., 2008) . We compared mRNA and protein levels of VDR and AHR in these cell lines. VDR mRNA expression levels in U937 cells, THP-1 cells, MCF-7 cells and HEK293 cells were 1,008 ± 126 copies, 51 ± 9 copies, 690
This article has not been copyedited and formatted. The final version may differ from this version. 16 ± 88 copies and 526 ± 28 copies/μg total RNA, respectively, while those for AHR were 856 ± 244 copies, 107 ± 19 copies, 7,232 ± 922 copies and 1,900 ± 217 copies/μg total RNA, respectively (Fig. 1B) . We next examined expression of nuclear VDR and AHR protein levels. As reported previously ), VDR protein expression was observed in U937 cells and, to a lesser extent, in THP-1 cells in the absence of ligand (Fig.1C) . BaP plus 1,25(OH) 2 D 3 increased VDR protein levels in these cells as well as in MCF-7 cells and HEK293 cells (Fig. 1C) . AHR protein expression was observed in all cell lines both with and without combined BaP and 1,25(OH) 2 D 3 treatment (Fig. 1C ).
There were some discrepancies between mRNA and protein levels of VDR and AHR (Fig.   1 , B and C). It may be due to translational or post-translational regulation of these proteins. As reported previously (Ishizawa et al., 2008; Matsunawa et al., 2009 ), 1,25(OH) 2 D 3 treatment effectively induced expression of the VDR target CYP24A1 in U937 cells and THP-1 cells (Fig. 1D) , indicating that VDR functions in these cells. BaP
(1 μM) did not induce CYP1A2 or CYP1B1 expression in U937 cells, and the combination of BaP and 1,25(OH) 2 D 3 had no effect on expression of these genes (Fig. 1E) (Fig. 3A) . We examined BaP hydroxylation activity by detecting conversion of BaP to 3-hydroxy-BaP. CYP1A1, but not CYP1A2 or CYP1B1, mediate this cellular reaction (Endo et al., 2008) . Cells were treated with BaP and/or 1,25(OH) 2 D 3 for 24 hours, and microsomes were isolated for enzyme activity assays. BaP treatment effectively increased BaP hydroxylation activity in U937 cells (Fig. 3B) .
Interestingly, 1,25(OH) 2 D 3 slightly increased BaP hydroxylation activity in U937 cells (Fig. 3B) , consistent with CYP1A1 protein expression ( (Fig. 3A) . BaP treatment also increased BaP hydroxylation activity in THP-1 cells, but the enzyme activity levels were very weak when compared to U937 cells (Fig. 3B) . This difference is likely due to lower CYP1A1 protein levels in THP-1 cells (Fig. 3A) . BaP-DNA adducts in these cells (Fig. 3C) . Therefore, BaP and 1,25(OH) 2 D 3 co-treatment increases CYP1A1 protein levels, BaP hydroxylation activity and BaP-DNA adduct formation in U937 cells and THP-1 cells.
Both VDR Activation and AHR Activation are Involved in CYP1A1
Transcription. VDR is activated by LCA and its derivatives, such as LCA acetate, as well as 1,25(OH) 2 D 3 (Ishizawa et al., 2008) . LCA acetate alone did not induce CYP1A1 mRNA expression in U937 cells (Fig. 4A) (Fig. 4B ). In addition, we examined the effect of VDR antagonists, ADTT and ADMI3 (Igarashi et al., 2007; Nakabayashi et al., 2008) . Both ADTT and ADMI3
effectively reduced CYP1A1 expression induced by BaP plus 1,25(OH) 2 D 3 in THP-1 cells (Fig. 4C) . Thus, VDR activation is involved in effective CYP1A1 induction.
The effect of 1,25(OH) 2 D 3 on CYP1A1 expression was examined in U937 cells treated with TCDD. TCDD is a high-affinity AHR ligand that is virtually not metabolized in cells (Bock and Kohle, 2006) . 1,25(OH) 2 D 3 increased CYP1A1 expression induced by TCDD (Fig. 4D) . Next, we examined the effect of α-naphthoflavone, an AHR antagonist (Gasiewicz and Rucci, 1991 VDR-RXR Binds to the CYP1A1 Promoter. VDR, PXR and CAR belong to the NR1I subfamily of the nuclear receptor superfamily and regulate common target genes, such as CYP3A4 (Makishima et al., 2002; Thummel et al., 2001; Xie et al., 2000) . The
This article has not been copyedited and formatted. The final version may differ from this version. CAR-RXR heterodimer binds to an ER8 element in the human CYP1A1 promoter (Yoshinari et al., 2010) . We performed EMSAs using oligonucleotide probes containing the ER8 element and a known xenobiotic-responsive element (XRE) (WT in Fig. 5A ).
The VDR-RXR heterodimer bound to isotope-labeled XRE-ER8 (Fig. 5B) . Complex formation was inhibited by addition of unlabeled XRE-ER8 (Fig. 5B) . Mutation of the XRE and a proximal half-site of ER8 (MT2 in Fig. 5A ) inhibited binding of VDR-RXR to isotope-labeled wild-type XRE-ER8 but mutation of both hexanucleotides of ER8 (MT1 in Fig. 5A ) failed to exhibit competition (Fig. 5B) . Addition of anti-VDR antibody induced a supershift of the VDR-RXR complex with XRE-ER8 (Fig. 5B) . The results indicate that VDR-RXR directly binds to ER8 in the CYP1A1 promoter.
Finally, we performed ChIP assays to examine direct VDR binding to the CYP1A1 promoter in cells using anti-AHR or anti-VDR antibodies and PCR for the -379 to -693 CYP1A1 promoter region, which contains the XRE (-489 to -495) and the ER8 (-506 to -525) (Fig. 5A ). Six hours after ligand addition, BaP and 1,25(OH) 2 D 3 recruited AHR and VDR, respectively, to the CYP1A1 promoter in U937 cells, and combination of these compounds did not further increase the recruitment of AHR or VDR (Fig. 5C ). At 24 hours, VDR recruitment was slightly higher with BaP plus 1,25(OH) 2 D 3 compared to treatment of 1,25(OH) 2 D 3 alone (Fig. 5C ). BaP and 1,25(OH) 2 D 3 also induced recruitment of AHR and VDR, respectively, to the CYP1A1 promoter in THP-1 cells (Fig.   5D ). Therefore, VDR regulates CYP1A1 transcription by direct binding to the promoter in This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
We show here that VDR activation enhanced the CYP1A1 expression and activity induced by AHR ligands in monocyte/macrophage-derived U937 cells and THP-1 cells.
EMSA and ChIP assays demonstrate that VDR binds to the ER8 motif located in the proximal promoter of the human CYP1A1 gene. CAR, another NR1I subfamily nuclear receptor, also binds to the same motif and its activation induces expression of both CYP1A1 and CYP1A2 in hepatocytes (Yoshinari et al., 2010) . In contrast to CYP1A1 induction, the combined treatment of BaP and 1,25(OH) 2 D 3 did not induce CYP1A2 expression in U937 cells (Fig. 1) . While administration of BaP to mice induces Cyp1a1 mRNA levels in liver, small intestine, spleen and bone marrow, it induces Cyp1a2 mRNA expression in liver, small intestine and to a lesser degree in spleen, but not in bone marrow (Uno et al., 2006) . Although the human CYP1A1 and CYP1A2 genes are located in a head-to-head orientation on chromosome 15 and share a common regulatory region (Ueda et al., 2006) , transcription of these genes may be regulated by additional tissue-or cell-type-specific mechanisms. Bone marrow-derived cells may be less responsible for
While CAR activation induces expression of CYP1A1 and CYP1A2 independent of AHR (Yoshinari et al., 2010) , use of an AHR antagonist, α-naphthoflavone, shows that the effect of 1,25(OH) 2 D 3 on CYP1A1 induction requires AHR activation (Fig. 4) . These
findings indicate that VDR signaling is only effective in augmenting CYP1A1
This article has not been copyedited and formatted. The final version may differ from this version. BaP-DNA adduct formation (Fig. 3) . BaP is first oxidized by CYP1A1 and CYP1B1 to phenols, such as 3-hydroxy-BaP and 9-hydroxy-BaP, and epoxides, such as BaP-7,8-epoxide (Shimada and Fujii-Kuriyama, 2004) . We observed enhanced BaP hydroxylation to 3-hydroxy-BaP in cells treated with BaP and 1,25(OH) 2 D 3 (Fig. 3) BaP-7,8-diol-9,10-epoxide (Shimada and Fujii-Kuriyama, 2004 ). BaP-7,8-diol is also metabolized to BaP-7,8-dione by aldoketoreductase, and BaP-1,3-, 1,6-, and 3,6-diones are thought to be formed by metabolism of BaP to phenols by CYP enzymes (Shimada, 2006) . These BaP quinones are also involved in DNA adduct formation. Glutathione S-transferase suppresses BaP-induced DNA adduct formation by conjugation of reactive BaP metabolites ). The formation of BaP-induced DNA adducts is decreased in Hepa-1 c37 cells, a CYP1A1-deficient mutant clone of Hepa-1 cells (Maier et al., 2002) . Stable transfection of a Cyp1a1 expression plasmid restores adduct formation to the level of parent Hepa-1 cells (Maier et al., 2002) . Exogenous expression of the oncogenic AML1-ETO fusion protein in U937 cells up-regulates CYP1A1 expression and increases BaP-DNA adduct formation (Xu et al., 2007) . These findings are similar to our result showing that CYP1A1 induction by BaP plus 1,25(OH) 2 D 3 was associated with BaP-DNA adduct formation (Fig. 3C) . By contrast, DNA adduct formation is increased in CYP1A1-deficient mice (Uno et al., 2004) , and overexpression of CYP1A1 in hepatocytes suppresses BaP-induced DNA adduct formation (Endo et al., 2008) . CYP1A2 is also involved in the suppression of BaP-DNA adduct formation but it does not cause 3-hydroxy-BaP formation (Endo et al., 2008) . CYP1A1 is involved in the phase I metabolism of xenobiotics, such as BaP, and endogenous compounds, including estradiol and eicosanoids (Nebert and Karp, 2008; Uno and Makishima, 2005) . Induced differentiation of myeloid leukemia cells by 1,25(OH) 2 D 3 is associated with increased expression of enzymes involved in eicosanoid metabolism, such as arachidonate 5-lipoxygenase and prostaglandin-endoperoxide synthase 1 Matsunawa et al., 2009) . Prostaglandin production plays a role in inducing differentiation of myeloid leukemia cells (Rocca et al., 2004) . CYP1A1 
